OncoVista Innovative Therapies Inc. (OVIT)
OTC PINK OTC PINK Primary Summary
OncoVista Innovative Therapies Inc. (OVIT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has OncoVista Innovative Therapies Inc. ever had a stock split?
OncoVista Innovative Therapies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alexander L. Weis CEO | OTC PINK Exchange | 68232J105 CUSIP |
| US Country | 2 Employees | - Last Dividend | 29 Oct 2007 Last Split | - IPO Date |
Overview
OncoVista Innovative Therapies, Inc. is a biopharmaceutical company focused on the development of targeted anticancer therapies. Leveraging tumor-associated biomarkers, the company aims to advance the treatment of cancer with more precision. Founded in 2004 and headquartered in San Antonio, Texas, OncoVista is committed to providing innovative solutions for managing cancer, focusing on unmet medical needs and improving patient outcomes.
Products and Services
Cordycepin (OVI-123): This leading product candidate is currently in Phase I/II clinical trials, targeting the treatment of refractory TdT positive leukemias. The development of Cordycepin is based on its potential to address specific leukemias that have proven resistant to conventional treatments, demonstrating OncoVista's commitment to tackling hard-to-treat cancers.
L-Nucleoside Conjugates (OVI-117): Positioned in the pre-clinical development stage, this product targets the treatment of colon cancer. By focusing on a therapy for one of the most common cancers, OVI-117 represents an important step in realizing the company's vision of targeted cancer treatments, showing promise for a broad impact on cancer care.
